Cat’s Claw / Casp3 Cancer Research Results

Cats, Cat’s Claw: Click to Expand ⟱
Features:
Cat’s Claw (Uncaria tomentosa) – Known for its immune-boosting properties.
Dose: Tea 1-2g, 1-3x/d. Extract 250-500mg/d

Cat’s Claw — usually refers to extracts of Uncaria tomentosa bark, a South American medicinal vine used as a botanical mixture rather than a single defined molecule. It is best classified as a phytotherapeutic natural-product extract with immunomodulatory, anti-inflammatory, and context-dependent cytotoxic activity. Common abbreviations include UT and, less specifically, cat’s claw. Major constituent classes include pentacyclic oxindole alkaloids, tetracyclic oxindole alkaloids, proanthocyanidins, quinovic acid glycosides, and related polyphenols/triterpenes. In oncology, the main issue is heterogeneity: chemotype, extraction solvent, and alkaloid/proanthocyanidin composition can shift the dominant biology, so “Cat’s Claw” should not be treated as a pharmacologically uniform agent.

Primary mechanisms (ranked):

  1. Immune-inflammatory signaling modulation centered on TNF-α / NF-κB suppression
  2. Intrinsic apoptosis induction in susceptible cancer cells via mitochondrial signaling, cytochrome c release, caspase activation, Bax↑ and anti-apoptotic Bcl-family restraint↓
  3. Redox modulation with context-dependent ROS effects; antioxidant/cytoprotective activity in inflammatory or normal-cell settings, but pro-oxidant stress can contribute to cancer-cell killing in some models
  4. MAPK-pathway modulation and downstream cytokine reprogramming
  5. Adjunctive chemotherapy interaction biology, including reported enhancement of treatment-induced apoptosis or differential protection of normal vs malignant cells in some preclinical systems
  6. Transporter / drug-metabolism interaction potential, relevant to clinical translation more than to direct anticancer effect

Bioavailability / PK relevance: Human PK is not well standardized because Cat’s Claw is a multicomponent extract and marketed products vary widely. Standardization usually focuses on pentacyclic oxindole alkaloids, but different fractions can behave differently and mixed chemotypes may not be therapeutically equivalent. Practical translation is therefore constrained more by extract identity and interaction liability than by a clean single-agent PK model.

In-vitro vs systemic exposure relevance: Much of the direct anticancer literature uses crude extracts or fraction concentrations that are difficult to map to reproducible systemic exposure in humans. That makes the anti-inflammatory and supportive-care signals more clinically grounded than claims of reliable direct tumor cytotoxicity. Concentration-response findings should therefore be interpreted as extract-specific and often preclinical rather than as evidence of achievable human tumor exposure.

Clinical evidence status: Small human adjunct/supportive-care evidence exists, but there is no convincing clinical evidence that Cat’s Claw produces objective anticancer responses as a stand-alone treatment. Randomized/controlled oncology data are limited to supportive-care settings, with one breast-cancer adjuvant study reporting reduced chemotherapy-associated neutropenia/DNA damage and a colorectal-cancer trial showing no clear benefit on measured chemotherapy side effects; a phase II advanced-solid-tumor study suggested quality-of-life and fatigue improvement without objective tumor responses.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 TNF-α / NF-κB inflammatory transcription ↓ TNF-α signaling; ↓ NF-κB-dependent survival/inflammatory tone (model-dependent) ↓ inflammatory activation and cytokine stress R-G Anti-inflammatory reprogramming Most reproducible cross-model axis; likely central for supportive-care rationale and some indirect anticancer effects.
2 Mitochondrial apoptosis Bax ↑; Bcl-xL/Bcl-2 restraint ↓; cytochrome c release ↑; caspases ↑; apoptosis ↑ Usually limited direct toxicity at tested supportive doses, but extract-dependent R-G Direct tumor-cell killing Strongest direct anticancer signal is in leukemia and selected solid-tumor models; activity depends heavily on fraction/chemotype.
3 ROS balance ROS ↑ in some cancer models; in other systems oxidative damage/lipid peroxidation ↓ ROS stress ↓ and cytoprotection ↑ are commonly reported P-R Context-dependent redox control Cat’s Claw is not a simple pro-oxidant or antioxidant. Cancer-cell apoptosis can be ROS-linked, whereas normal/inflammatory settings often show antioxidant behavior.
4 MAPK signaling MAPK signaling ↓ with altered cytokine program Inflammatory MAPK tone ↓ R Cytokine and survival-pathway modulation Supports the TNF-α / NF-κB story rather than standing fully separate from it.
5 DNA damage response / leukocyte recovery No established direct antitumor DDR mechanism DNA repair capacity / leukocyte recovery ↑ (reported in adjunct settings) G Host-supportive adjunct effect Clinically relevant because the best human oncology signals are supportive rather than tumoricidal.
6 Chemosensitization / differential normal-cell protection Apoptosis with chemotherapy ↑ in some models; cisplatin sensitivity may ↑ Normal-cell oxidative injury may ↓ in some models G Adjunct treatment modulation Potentially useful but still preclinical and extract-specific; dual cancer-sensitizing plus normal-tissue-protective framing is not yet clinically secure.
7 Drug transporters and metabolism May alter exposure to co-administered anticancer drugs indirectly Same G Interaction liability Reported CYP3A4/PXR/transporter effects make combination use clinically important even though this is not a tumor-targeting mechanism.
8 Clinical Translation Constraint Direct anticancer efficacy uncertain Tolerability generally acceptable short term G Standardization and trial limitation Major constraint is product heterogeneity: bark vs leaf, aqueous vs ethanolic, POA-rich vs PAC-rich, and mixed chemotypes can produce materially different biology.

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
5914- Cats,    Induction of apoptosis by Uncaria tomentosa through reactive oxygen species production, cytochrome c release, and caspases activation in human leukemia cells
- in-vitro, AML, HL-60
*Inflam↓, eff↑, DNAdam↑, Cyt‑c↑, Casp3↑, PARP↑, Fas↑, proCasp8↑, cl‑BID↑, BAX↑, Bcl-xL↑, cl‑Mcl-1↑,
5919- Cats,  Cisplatin,    Uncaria tomentosa Leaves Decoction Modulates Differently ROS Production in Cancer and Normal Cells, and Effects Cisplatin Cytotoxicity
- in-vitro, Liver, HepG2
ROS↑, GSH↓, Apoptosis↑, Casp3↑, Casp7↑, NF-kB↓, selectivity↑, ChemoSen↑, chemoP↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-xL↑, 1,   cl‑BID↑, 1,   Casp3↑, 2,   Casp7↑, 1,   proCasp8↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,   cl‑Mcl-1↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   PARP↑, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 19

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:221  Target#:42  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page